Description
What is Tesamorelin?
-
Scientific name: Tesamorelin acetate
-
Class: Growth hormone–releasing hormone (GHRH) analog
-
Molecular weight: ~5,000 Daltons
-
Administration: Subcutaneous injection
-
Approval: FDA-approved in 2010 (brand name Egrifta®) for HIV-related visceral adiposity
Tesamorelin is structurally modified to resist enzymatic breakdown, giving it a longer half-life than natural GHRH.
Mechanism of Action
Tesamorelin binds to GHRH receptors in the pituitary gland, stimulating the release of endogenous growth hormone (GH). This leads to increased secretion of insulin-like growth factor 1 (IGF-1),which plays a role in:
-
Fat metabolism
-
Protein synthesis
-
Muscle growth and maintenance
-
Tissue repair and regeneration
Clinical Benefits of Tesamorelin
1. FDA-Approved Use
-
HIV-associated lipodystrophy:
-
Reduces visceral adipose tissue (VAT) in the abdominal region
-
Improves body composition and quality of life
-
2. Investigational / Research Uses
Studies and ongoing research suggest Tesamorelin may offer additional benefits:
-
Anti-aging and longevity research – increasing GH and IGF-1 levels may support muscle mass, reduce frailty, and improve skin health
-
Cognitive function – early studies suggest possible benefits in age-related cognitive decline and Alzheimer’s disease
-
Metabolic health – potential improvement in lipid metabolism, fat distribution, and insulin sensitivity
-
Tissue repair & recovery – may aid in muscle regeneration and wound healing
Dosage & Administration (Approved Use)
-
Standard dose: 2 mg once daily via subcutaneous injection
-
Duration: Treatment is ongoing, as discontinuation may cause fat redistribution to return
-
Form: Lyophilized powder for reconstitution
Note: Research applications may explore different dosing strategies, but only FDA-approved protocols are validated for safety and efficacy.
Side Effects and Safety
Like all peptide therapies, Tesamorelin has possible side effects:
-
Common: Injection site redness, rash, joint pain, mild swelling, muscle aches
-
Hormonal: Increased IGF-1 levels, possible impact on glucose tolerance
-
Rare: Hypersensitivity reactions
-
Contraindications: Pregnancy, active malignancy, known hypersensitivity to Tesamorelin or mannitol
Storage and Stability
-
Store lyophilized vials refrigerated (2–8 °C)
-
Protect from light and moisture
-
After reconstitution, use within recommended time (usually 24–48 hours if refrigerated, depending on manufacturer).
Reviews
There are no reviews yet.